"uuid:ID","name","instanceType","label","id","description","rationale"
"5a1badbd-f5ba-45ac-a0bf-05f9b6e91eae","Study Design 1","StudyDesign","","StudyDesign_1","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
